Logo image of BRSH

BRUUSH ORAL CARE INC (BRSH) Stock Fundamental Analysis

NASDAQ:BRSH - Nasdaq - CA11750K4019 - Common Stock - Currency: USD

0.086  +0.01 (+14.67%)

After market: 0.049 -0.04 (-43.02%)

Fundamental Rating

1

Overall BRSH gets a fundamental rating of 1 out of 10. We evaluated BRSH against 37 industry peers in the Personal Care Products industry. BRSH may be in some trouble as it scores bad on both profitability and health. BRSH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BRSH has reported negative net income.
BRSH Yearly Net Income VS EBIT VS OCF VS FCFBRSH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of BRSH (-842.47%) is worse than 97.30% of its industry peers.
Industry RankSector Rank
ROA -842.47%
ROE N/A
ROIC N/A
ROA(3y)-446.31%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRSH Yearly ROA, ROE, ROICBRSH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 -2K -4K

1.3 Margins

The Gross Margin of BRSH (70.01%) is better than 67.57% of its industry peers.
The Profit Margin and Operating Margin are not available for BRSH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRSH Yearly Profit, Operating, Gross MarginsBRSH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -200 -400 -600 -800

More info and screens

1

2. Health

2.1 Basic Checks

BRSH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BRSH remains at a similar level compared to 1 year ago.
BRSH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRSH Yearly Shares OutstandingBRSH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 100K 200K 300K
BRSH Yearly Total Debt VS Total AssetsBRSH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 500K 1M 1.5M 2M

2.2 Solvency

Based on the Altman-Z score of -102.76, we must say that BRSH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -102.76, BRSH is not doing good in the industry: 97.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -102.76
ROIC/WACCN/A
WACC25.48%
BRSH Yearly LT Debt VS Equity VS FCFBRSH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 -2M -4M -6M -8M -10M

2.3 Liquidity

BRSH has a Current Ratio of 0.15. This is a bad value and indicates that BRSH is not financially healthy enough and could expect problems in meeting its short term obligations.
BRSH has a Current ratio of 0.15. This is amonst the worse of the industry: BRSH underperforms 97.30% of its industry peers.
A Quick Ratio of 0.12 indicates that BRSH may have some problems paying its short term obligations.
BRSH's Quick ratio of 0.12 is on the low side compared to the rest of the industry. BRSH is outperformed by 94.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.12
BRSH Yearly Current Assets VS Current LiabilitesBRSH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 500K 1M 1.5M 2M 2.5M

More info and screens

1

3. Growth

3.1 Past

BRSH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.99%, which is quite impressive.
BRSH shows a strong growth in Revenue. In the last year, the Revenue has grown by 192.22%.
EPS 1Y (TTM)95.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)192.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BRSH Yearly Revenue VS EstimatesBRSH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 500K 1M 1.5M 2M 2.5M
BRSH Yearly EPS VS EstimatesBRSH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BRSH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRSH Price Earnings VS Forward Price EarningsBRSH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRSH Per share dataBRSH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BRSH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRUUSH ORAL CARE INC

NASDAQ:BRSH (6/27/2024, 8:06:01 PM)

After market: 0.049 -0.04 (-43.02%)

0.086

+0.01 (+14.67%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners0.32%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.41M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.86
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.18
BVpS-0.32
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -842.47%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.01%
FCFM N/A
ROA(3y)-446.31%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover3.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.12
Altman-Z -102.76
F-ScoreN/A
WACC25.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)192.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-210.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.86%
OCF growth 3YN/A
OCF growth 5YN/A